CLINDAMYCIN INJECTION IN 5% DEXTROSE 600 MG / 50 ML
CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) : 600 MG / 50 ML · DIN 02485478 · BAXTER CORPORATION
Health Canada status: MARKETED
What is CLINDAMYCIN INJECTION IN 5% DEXTROSE?
CLINDAMYCIN INJECTION IN 5% DEXTROSE 600 MG / 50 ML contains CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) : 600 MG / 50 ML. It is listed in the Health Canada Drug Product Database under DIN 02485478, held by BAXTER CORPORATION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 26-Nov-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CLINDAMYCIN INJECTION IN 5% DEXTROSE used for?
Serious infections due to susceptible anaerobic and gram-positive aerobic bacteria (e.g., lower respiratory, skin, gynecological, intra-abdominal, septicemia, bone/joint, Pneumocystis jiroveci).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02485478 |
|---|---|
| Brand name | CLINDAMYCIN INJECTION IN 5% DEXTROSE |
| Generic / active ingredient | CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) : 600 MG / 50 ML |
| Manufacturer | BAXTER CORPORATION |
| Strength | 600 MG / 50 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01FF01 CLINDAMYCIN |
| AHFS class | 08:12.28.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 26-Nov-2019 |
| Original market date | 2019-11-26 00:00:00 |
How is it administered?
Adults: 1200-2700 mg/day in 2-4 equal doses via IV infusion. Infusion rate not to exceed 30 mg/min. Not for bolus. Treatment for beta-hemolytic streptococcal infections should be ≥10 days.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. Do not freeze. Avoid excessive heat.
How is it supplied?
50 mL GALAXY plastic containers in a case of 24.
Contraindications
Hypersensitivity to clindamycin, lincomycin, or any ingredient in the formulation/container.
Warnings and precautions
Risk of Clostridium difficile-associated disease (CDAD). Severe hypersensitivity/skin reactions (SJS, TEN, DRESS). Potential nephrotoxicity. Not for meningitis (poor CSF penetration).
Is CLINDAMYCIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01FF01 CLINDAMYCIN. 24 of 59 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-CLINDAMYCIN | 150 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02436906 |
| AURO-CLINDAMYCIN | 300 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02436914 |
| CLINDAMYCIN | 150 MG | CAPSULE | SANIS HEALTH INC | MARKETED | DIN 02400529 |
| CLINDAMYCIN | 300 MG | CAPSULE | SANIS HEALTH INC | MARKETED | DIN 02400537 |
| CLINDAMYCIN INJECTION IN 5% DEXTROSE | 900 MG / 50 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02485486 |
| CLINDAMYCIN INJECTION USP | 150 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02230535 |
| CLINDAMYCIN INJECTION USP | 150 MG | LIQUID | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02230540 |
| CLINDAMYCIN IV INFUSION | 12 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02408511 |
| CLINDAMYCIN IV INFUSION | 18 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02408538 |
| DALACIN C FLAVOURED GRANULES | 75 MG / 5 ML | Granules For Solution | PFIZER CANADA ULC | MARKETED | DIN 00225851 |
Who else supplies CLINDAMYCIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CLINDAMYCIN appears in 270 registered pack listings across 12 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.